What does Iovance Biotherapeutics do?
IOVANCE Biotherapeutics is focused on improving patient care by making T cell-based immunotherapies broadly accessible for the treatment of patients with solid tumors and blood cancers.
Who founded Iovance?
Unsourced material may be challenged and removed. Iovance Biotherapeutics, Inc….Iovance Biotherapeutics.
Type | Public company |
---|---|
Founded | 2007 |
Headquarters | San Carlos, California , U.S. |
Key people | Steven Rosenberg |
Website | iovance.com |
Where is Iovance located?
Philadelphia, Pennsylvania
The Iovance Cell Therapy Center (iCTC), located in the heart of Cellicon Valley at the Navy Yard, Philadelphia, Pennsylvania, is the first centralized, scalable, state-of-the-art manufacturing facility dedicated to producing potentially life-saving TIL cell therapies for patients with solid tumor cancers.
What is Lifileucel?
Lifileucel is an autologous, centrally manufactured tumor-infiltrating lymphocyte product. Methods: We conducted a phase II open-label, single-arm, multicenter study in patients with advanced melanoma who had been previously treated with checkpoint inhibitor(s) and BRAF ± MEK targeted agents.
What is TIL therapy?
A type of treatment in which tumor-infiltrating lymphocytes (a type of immune cell that can recognize and kill cancer cells) are removed from a patient’s tumor and grown in large numbers in a laboratory.
What is tumor infiltrating lymphocytes?
Tumor infiltrating lymphocytes (TILs) consist of all lymphocytic cell populations that have invaded the tumor tissue. TILs have been described in a number of solid tumors, including breast cancer, and are emerging as an important biomarker in predicting the efficacy and outcome of treatment.
Is TIL therapy FDA approved?
FDA Grants Orphan Drug Designation to Novel TIL Therapy for Advanced-Stage Melanoma. The FDA has granted orphan drug designation to ITIL-168 for the treatment of stage IIB to IV melanoma, an investigational, autologous cell therapy derived from tumor-infiltrating lymphocytes.
How is TCC administered?
T-VEC is injected directly into the melanoma lesions. The second treatment must be administered three weeks after the initial injection. Patients receive subsequent doses every two-three weeks for six months or, for as long as you have tumors.
Are tumor-infiltrating lymphocytes good?
2.4. Tumor infiltrating lymphocytes (TILs) consist of all lymphocytic cell populations that have invaded the tumor tissue. TILs have been described in a number of solid tumors, including breast cancer, and are emerging as an important biomarker in predicting the efficacy and outcome of treatment.
Are TILs B cells?
Thus, CD20+ TILs have hallmarks of antigen-experienced, clonally expanded B cells. Drawing from the transplantation and autoimmunity fields, we considered several mechanisms to explain how CD20+ TILs could increase patient survival.
How effective is TIL therapy?
Although currently less-heralded and much less accessible than ipilimumab, TIL therapy is arguably more successful, with response rates of over 50% and durable complete response rates of 20% in patients with metastatic melanoma who have failed other therapies [4••].
Are TILs T cells?
Introduction. Tumor-infiltrating lymphocytes (TIL) are a polyclonal population that contains tumor-specific T cells with high frequency. These tumor-specific T cells mainly recognize neoantigens resulting from somatic mutations in cancer cells.